Apellis Pharmaceuticals (APLS) said Tuesday that the US Food and Drug Administration has accepted its supplemental new drug application for Empaveli, or pegcetacoplan, to treat C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis, both rare kidney diseases.
The company said the application is based on results from a late-stage trial that achieved its primary endpoint of "statistically significant" reduction in proteinuria and indicated stabilization of kidney function in patients treated with Empaveli.
The agency granted the application Priority Review and scheduled a decision date of July 28, Apellis said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.